Lawyers in our Mass Torts Section continue to evaluate hundreds of Actos claims for individuals who have been diagnosed with urinary bladder cancer after ingesting Actos to treat their type-2 diabetes. Actos is manufactured and marketed by Takeda Pharmaceuticals, a Japanese pharmaceutical company with U.S. operations headquartered in Illinois. Actos is currently marketed as a stand-alone drug and well as in combination with metformin (Actoplus Met), metformin extended release tablets (Actoplus Met XR), and glimepiride (Duetact), all of which are designed to treat type-2 diabetes.
The Judicial Panel on Multidistrict Litigation met on December 1, 2011, in Savannah, Georgia, to consider MDL No. 2299, In re: Actos Products Liability Litigation. The seven district judge panel heard oral arguments on motions seeking the coordination and transfer of all Actos cases pending in the federal court system to a single United States District Judge for coordinated pretrial proceedings. After hearing oral arguments, the panel recently determined that centralization of the Actos litigation in the Western District of Louisiana would serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation.
If you or someone you know has been diagnosed with bladder cancer after taking Actos, or you need more information on this subject, call Roger Smith, a lawyer in our Mass Torts Section at 800-898-2034 or by email at Roger.Smith@beasleyallen.com. We are happy to work with anybody to investigate your potential case.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.